Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).
Jean-Yves Blay
Consultant or Advisory Role - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - MSD (U)
Lin Shen
Research Funding - Roche
Yoon-Koo Kang
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer; Novartis
Piotr Rutkowski
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Shukui Qin
No relevant relationships to disclose
Dmitry Nosov
No relevant relationships to disclose
Steven C. Novick
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Lilia Taningco
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Shuyuan Mo
Employment or Leadership Position - Novartis
Peter Reichardt
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
George D. Demetri
Consultant or Advisory Role - ARIAD; Blueprint Medicines; Champions Biotechnology; Foundation Medicine; G1 Therapeutics; GlaxoSmithKline; Johnson & Johnson; Kolltan Pharmaceuticals; Merck; Merrimack; N-of-One (U); Novartis; Pfizer; Sanofi ; ZIOPHARM Oncology
Stock Ownership - Blueprint Medicines; Champions Biotechnology; G1 Therapeutics; Kolltan Pharmaceuticals; N-of-One
Research Funding - GlaxoSmithKline; Johnson & Johnson; Merck; Novartis; Pfizer; Sanofi
Expert Testimony - GlaxoSmithKline (U); Johnson & Johnson (U); Merck (U)